Top Stock Losers August 1 2025 saw a dramatic plunge across multiple biotech and healthcare stocks, shaking investor confidence and sending red waves through the NASDAQ and NYSE. Leading the losses was Healthcare Triangle Inc. (HCTI), which crashed nearly 100% in a single trading session, followed closely by Dermata Therapeutics Inc. (DRMA), which plummeted over 89%.
Let’s take a closer look at the top stock losers on August 1, 2025:
📉 Biggest Decliners of the Day:
-
Healthcare Triangle, Inc. (HCTI)
-
Price: $4.75
-
Change: −99.75%
-
HCTI shocked investors with a near-total collapse in share value, wiping out nearly all of its market capitalization. The plunge followed disappointing clinical trial data and potential bankruptcy speculation.
-
-
Dermata Therapeutics, Inc. (DRMA)
-
Price: $6.45
-
Change: −89.65%
-
DRMA suffered its worst day on record after reporting increased quarterly losses and receiving a warning from the FDA regarding a delayed approval process.
-
-
Psyence Biomedical Ltd. (PBM)
-
Price: $2.36
-
Change: −53.08%
-
PBM tumbled after missing earnings estimates and warning investors about liquidity issues heading into Q4.
-
-
TTEC Holdings, Inc. (TTEC)
-
Price: $3.09
-
Change: −37.95%
-
Customer experience platform TTEC Holdings fell nearly 38% due to a weaker-than-expected revenue outlook and industry-wide spending slowdowns.
-
-
Silexion Therapeutics Corp (SLXN)
-
Price: $9.28
-
Change: −37.88%
-
SLXN’s shares sank after early-stage trial data failed to meet analyst expectations, causing sharp sell-offs.
-
-
Recon Technology, Ltd. (RCON)
-
Price: $2.81
-
Change: −37.56%
-
RCON, a tech supplier to the oilfield services sector, faced a steep drop amid broader weakness in energy tech stocks and reports of regulatory concerns in Asia.
-
🔍 Market Reaction & Analyst Notes:
The biotech-heavy decline in the Top Stock Losers August 1 2025 list highlights growing investor caution in high-volatility sectors. Analysts point to overvaluation, poor trial outcomes, and tight capital markets as primary drivers of this intense sell-off.
Some fund managers have suggested that this could be a buying opportunity for risk-tolerant traders, but others urge patience until more clarity emerges regarding regulation and earnings in Q3.
📊 Final Thoughts
August 1st marked one of the most bearish trading days for small-cap and biotech names in recent memory. The top stock losers August 1 2025 reflect not only individual company setbacks but also larger concerns across speculative growth industries.
Investors are advised to stay vigilant, monitor earnings reports closely, and diversify positions to hedge against single-stock volatility.
